Literature DB >> 33330825

Interpretation of guidelines for the diagnosis and treatment of primary liver cancer (2019 edition) in China.

Guoteng Qiu1, Zhaoxing Jin1, Xin Chen1, Jiwei Huang1.   

Abstract

Primary liver cancer (PLC) is currently the fourth most common malignancy and accounts for the second most cancer-related deaths in China. Since 2017, a great deal of high-level evidence, and particularly evidence based on Chinese studies and practice, has emerged in terms of diagnosis, staging, and treatment. A new version of the guidelines for the management of PLC specifying the diagnosis and treatment of PLC (2019 edition) has recently been published. The guidelines feature major changes in the techniques for early diagnosis, the combination of surgery, local therapy, and systemic treatment, and the use of traditional Chinese medicine. The guidelines need to be further implemented in clinical practice to demonstrate their validity. 2020, National Center for Global Health and Medicine.

Entities:  

Keywords:  diagnosis; hepatocellular carcinoma; treatment

Year:  2020        PMID: 33330825      PMCID: PMC7731101          DOI: 10.35772/ghm.2020.01051

Source DB:  PubMed          Journal:  Glob Health Med        ISSN: 2434-9186


  34 in total

1.  Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

Authors:  Tito Livraghi; Franca Meloni; Michele Di Stasi; Emanuela Rolle; Luigi Solbiati; Carmine Tinelli; Sandro Rossi
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

2.  Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries.

Authors:  Hongmei Zeng; Wanqing Chen; Rongshou Zheng; Siwei Zhang; John S Ji; Xiaonong Zou; Changfa Xia; Kexin Sun; Zhixun Yang; He Li; Ning Wang; Renqiang Han; Shuzheng Liu; Huizhang Li; Huijuan Mu; Yutong He; Yanjun Xu; Zhentao Fu; Yan Zhou; Jie Jiang; Yanlei Yang; Jianguo Chen; Kuangrong Wei; Dongmei Fan; Jian Wang; Fangxian Fu; Deli Zhao; Guohui Song; Jianshun Chen; Chunxiao Jiang; Xin Zhou; Xiaoping Gu; Feng Jin; Qilong Li; Yanhua Li; Tonghao Wu; Chunhua Yan; Jianmei Dong; Zhaolai Hua; Peter Baade; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  Lancet Glob Health       Date:  2018-05       Impact factor: 26.763

3.  Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition).

Authors:  Shukui Qin
Journal:  Chin Clin Oncol       Date:  2012-09

4.  Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial.

Authors:  Ming Shi; Rong-Ping Guo; Xiao-Jun Lin; Ya-Qi Zhang; Min-Shan Chen; Chang-Qing Zhang; Wan Yee Lau; Jin-Qing Li
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

5.  Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma.

Authors:  Jian Zhou; Lei Yu; Xue Gao; Jie Hu; Jiping Wang; Zhi Dai; Jie-Fei Wang; Zhiyong Zhang; Shaohua Lu; Xiaowu Huang; Zheng Wang; Shuangjian Qiu; Xiaoying Wang; Guohuan Yang; Huichuan Sun; Zhaoyou Tang; Ying Wu; Hongguang Zhu; Jia Fan
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

6.  Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.

Authors:  Richard S Finn; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; René Gerolami; Chiara Caparello; Roniel Cabrera; Charissa Chang; Weijing Sun; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Jordi Bruix
Journal:  J Hepatol       Date:  2018-04-26       Impact factor: 25.083

Review 7.  Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis.

Authors:  Yoon Jin Lee; Jeong Min Lee; Ji Sung Lee; Hwa Young Lee; Bo Hyun Park; Young Hoon Kim; Joon Koo Han; Byung Ihn Choi
Journal:  Radiology       Date:  2015-01-05       Impact factor: 11.105

Review 8.  Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis.

Authors:  Xijiao Liu; Hanyu Jiang; Jie Chen; You Zhou; Zixing Huang; Bin Song
Journal:  Liver Transpl       Date:  2017-12       Impact factor: 5.799

9.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321

Review 10.  The clinical use of HVPG measurements in chronic liver disease.

Authors:  Jaime Bosch; Juan G Abraldes; Annalisa Berzigotti; Juan Carlos García-Pagan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-01       Impact factor: 46.802

View more
  6 in total

1.  Classification of hepatic venous tumor thrombus in hepatocellular carcinoma: should it describe tumor status or predict patient survival?

Authors:  Norihiro Kokudo; Wei Tang; Takashi Kokudo
Journal:  Hepatobiliary Surg Nutr       Date:  2021-08       Impact factor: 7.293

2.  Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China.

Authors:  Xiao-Qi Chen; Yun-Xia Zhao; Chuan-Lei Zhang; Xin-Ting Wang; Xin Zhang; Xi Chen; Chang-Wei Yuan; Qing Zhao; Xin-Ju Chen
Journal:  Drug Des Devel Ther       Date:  2022-05-17       Impact factor: 4.319

3.  Inhibition of SUMO2/3 antagonizes isoflurane-induced cancer-promoting effect in hepatocellular carcinoma Hep3B cells.

Authors:  Peng Wang; Na Xue; Chunyan Zhang; Shimin Shan; Zhongmin Jiang; Wenhan Wu; Xiaozhi Liu
Journal:  Oncol Lett       Date:  2021-02-10       Impact factor: 2.967

4.  Bioinformatics screening the novel and promising targets of curcumin in hepatocellular carcinoma chemotherapy and prognosis.

Authors:  Tingting Yang; Yibiao Chen; Jiexuan Xu; Jinyuan Li; Hong Liu; Naihua Liu
Journal:  BMC Complement Med Ther       Date:  2022-01-25

5.  Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma.

Authors:  Zhitao Chen; Tielong Wang; Chuanbao Chen; Xitao Hong; Jia Yu; Yihao Ma; Yiwen Guo; Changjun Huang; Xiaoshun He; Weiqiang Ju; Maogen Chen
Journal:  J Oncol       Date:  2021-10-19       Impact factor: 4.375

6.  A retrospective study of enteral nutrition on immune and inflammatory factors after liver cancer surgery.

Authors:  Yao Xu; Feng-Xiang Wei
Journal:  Medicine (Baltimore)       Date:  2021-11-05       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.